Aug 16, 2021 / 12:00PM GMT
Operator
Good day, and thank you for standing by. Welcome to Sesen Bio Business Update. (Operator Instructions) Please be advised that today's conference is being recorded. (Operator Instructions)
I would now like to hand the conference over to your speaker today, Erin Clark, VP of Corporate Strategy and Investor Relations. Please go ahead.
Erin Clark - Sesen Bio, Inc. - VP of Corporate Strategy & IR
Thank you, and good morning, everyone. Thanks for joining us on today's call. With me today is Dr. Thomas Cannell, President and Chief Executive Officer, to discuss the complete response letter we received last Friday, August 13, from the FDA.
I would like to remind you that today's discussion will include forward-looking statements related to company's current plans and expectations, which are subject to risks and uncertainties. Actual results may differ materially due to various factors, including those described in Sesen Bio's most recent annual report on Form 10-K, quarterly report on Form 10-Q, and other SEC filings. These statements represent
Sesen Bio Inc Vicineum Biologics License Application FDA Response Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot